PCM
BSX icon

Prelude Capital Management’s Boston Scientific BSX Stock Holding History

Prelude Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$3K – 1633
2017
Q2 		$3K Buy
+100
New +$2.65K ﹤0.01% 1493

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prelude Capital Management's BSX Position: Q2 2026 in Review

Prelude Capital Management sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 5,253 shares — an estimated $330K sold.

Prelude Capital Management first reported a position in BSX in Q2 2013 and held it in 30 quarters. The position peaked at $4.06M in Q3 2025. 1,481 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Prelude Capital Management reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 5,253 Boston Scientific shares in Q2 2026, an estimated $330K.
  • Prelude Capital Management first reported a position in Boston Scientific in Q2 2013 and held it in 30 quarters.
  • Prelude Capital Management's Boston Scientific position peaked at $4.06M in Q3 2025.
  • 1,481 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.